[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112016028674A2 - ?1h-1, 8-naftiridin-2-onas como compostos antiproliferativos? - Google Patents

?1h-1, 8-naftiridin-2-onas como compostos antiproliferativos?

Info

Publication number
BR112016028674A2
BR112016028674A2 BR112016028674A BR112016028674A BR112016028674A2 BR 112016028674 A2 BR112016028674 A2 BR 112016028674A2 BR 112016028674 A BR112016028674 A BR 112016028674A BR 112016028674 A BR112016028674 A BR 112016028674A BR 112016028674 A2 BR112016028674 A2 BR 112016028674A2
Authority
BR
Brazil
Prior art keywords
naphthyridin
ones
antiproliferative compounds
compounds
antiproliferative
Prior art date
Application number
BR112016028674A
Other languages
English (en)
Inventor
Kompella Amala
Reddy Sirigireddy Balakrishna
Satya Bhujanga Rao Adibhatla Kali
Ganganamoni Srinivasulu
Chowdary Nannapaneni Venkaiah
Krishna GAMPA Venugopala
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52589723&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016028674(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of BR112016028674A2 publication Critical patent/BR112016028674A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

a presente invenção refere-se a novas 1h-1, 8-naftiridin-2-onas antiproliferativas da fórmula geral (i) ou seus sais farmaceuticamente aceitáveis: em que os grupos variáveis são como aqui definidos e a sua preparação e utilização no tratamento terapêutico de distúrbios relacionados à inibição de tirosina-quinases em animais de sangue quente. os compostos podem superar a resistência a fármacos induzida por imatinib.
BR112016028674A 2014-06-06 2014-12-15 ?1h-1, 8-naftiridin-2-onas como compostos antiproliferativos? BR112016028674A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2781CH2014 2014-06-06
PCT/IN2014/000777 WO2015186137A1 (en) 2014-06-06 2014-12-15 1h-1,8- naphthyridin-2ones as anti proliferative compounds

Publications (1)

Publication Number Publication Date
BR112016028674A2 true BR112016028674A2 (pt) 2017-08-22

Family

ID=52589723

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016028674A BR112016028674A2 (pt) 2014-06-06 2014-12-15 ?1h-1, 8-naftiridin-2-onas como compostos antiproliferativos?

Country Status (18)

Country Link
US (2) US9765072B2 (pt)
EP (1) EP3152205A1 (pt)
JP (1) JP2017516867A (pt)
KR (1) KR20170016921A (pt)
CN (1) CN106573929A (pt)
AP (1) AP2016009604A0 (pt)
AU (1) AU2014396394A1 (pt)
BR (1) BR112016028674A2 (pt)
CA (1) CA2950250A1 (pt)
CL (1) CL2016003102A1 (pt)
EA (1) EA201692371A1 (pt)
HK (1) HK1231469A1 (pt)
IL (1) IL249118A0 (pt)
MA (1) MA39524A1 (pt)
MX (1) MX2016015350A (pt)
PH (1) PH12016502432A1 (pt)
SG (1) SG11201610149YA (pt)
WO (1) WO2015186137A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201610149YA (en) * 2014-06-06 2017-01-27 Natco Pharma Ltd 1h-1,8- naphthyridin-2ones as anti proliferative compounds
CN107663151B (zh) * 2016-07-28 2021-11-26 江苏豪森药业集团有限公司 甲磺酸氟马替尼的中间体合成方法
CN108473476B (zh) * 2016-10-13 2021-02-19 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基杂环类化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2761180T3 (es) 2005-12-23 2020-05-19 Ariad Pharma Inc Compuestos bicíclicos de heteroarilo
CN101489558A (zh) * 2006-05-08 2009-07-22 阿里亚德医药股份有限公司 炔类杂芳基化合物
AU2007249924B2 (en) * 2006-05-08 2013-07-04 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
EP2937345B1 (en) * 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
RU2524210C2 (ru) 2010-01-29 2014-07-27 Ханми Сайенс Ко., Лтд. ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗЫ
SG11201610149YA (en) * 2014-06-06 2017-01-27 Natco Pharma Ltd 1h-1,8- naphthyridin-2ones as anti proliferative compounds

Also Published As

Publication number Publication date
US10047088B2 (en) 2018-08-14
EP3152205A1 (en) 2017-04-12
US9765072B2 (en) 2017-09-19
CL2016003102A1 (es) 2017-06-23
US20170114057A1 (en) 2017-04-27
AU2014396394A1 (en) 2016-12-08
AP2016009604A0 (en) 2016-12-31
SG11201610149YA (en) 2017-01-27
MA39524A1 (fr) 2018-01-31
CA2950250A1 (en) 2015-12-10
PH12016502432A1 (en) 2017-03-06
US20170349588A1 (en) 2017-12-07
JP2017516867A (ja) 2017-06-22
MX2016015350A (es) 2017-05-10
KR20170016921A (ko) 2017-02-14
WO2015186137A1 (en) 2015-12-10
EA201692371A1 (ru) 2017-04-28
CN106573929A (zh) 2017-04-19
HK1231469A1 (zh) 2017-12-22
IL249118A0 (en) 2017-01-31

Similar Documents

Publication Publication Date Title
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
CY1124243T1 (el) Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
EA201892207A1 (ru) Индолкарбоксамидные соединения
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
BR112016012860A2 (pt) Compostos de biarila úteis no tratamento de doenças humanas em oncologia, neurologia e imunologia
EA201792116A1 (ru) Ингибитор янус-киназы
BR112017005917A2 (pt) processos e composições para indução de imunidade protetora contra infecção com o vírus da imunodeficiência humana
EA201990833A1 (ru) Соединение пиридина
CY1119615T1 (el) Διπλα εκλεκτικοι αναστολεις ρι3 δελτα και γαμμα κινασης
WO2016100347A3 (en) Small molecule inhibitors of egfr and pi3k
BR112018005861A2 (pt) derivados de ácido oleanólico modificado com c4 para a inibição de il-17 e outros usos
EA201790745A1 (ru) Трициклические соединения
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
CY1122180T1 (el) Ανταγωνιστης υποδοχεα νκ-1/νκ-3 για τη θεραπευτικη αγωγη εξαψεων
MY201535A (en) Therapeutic compounds
BR112016030730A8 (pt) composto
BR112017002260A2 (pt) derivados de piperazina como moduladores do receptor x do fígado
BR112016028674A2 (pt) ?1h-1, 8-naftiridin-2-onas como compostos antiproliferativos?

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2544 DE 08-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.